Streamlining Otezla Prior Authorization for Oncology Patients

Otezla Prior Authorization in the Oncology Context

Otezla, an oral medication, is primarily indicated for conditions such as psoriatic arthritis, psoriasis, and Behçet's disease. While not an oncology drug, patients receiving cancer care frequently present with comorbidities requiring medications like Otezla. Obtaining prior authorization for Otezla in these patients necessitates navigating the payer's pharmacy benefit processes while coordinating with the intensive PA landscape of oncology.

Documentation Considerations for Otezla PA within Oncology

• Confirmation of the specific diagnosis for which Otezla is prescribed (e.g., psoriatic arthritis), distinct from the oncology diagnosis.
• Documentation of prior therapies attempted or contraindications to alternative treatments, as per Otezla's approved indications.
• Patient's current medication list, including all active cancer treatments, to assess potential drug interactions or contraindications.
• Performance status (e.g., ECOG or Karnofsky score), which may be relevant to overall treatment tolerance in an oncology patient.
• Relevant laboratory results supporting medical necessity for Otezla, alongside comprehensive oncology diagnostics.

Navigating Oncology-Specific Prior Authorization Complexities

Oncology prior authorization is characterized by high volume and intricate requirements, spanning J-code chemotherapy, advanced imaging, radiation therapy, and specialty oral oncolytics. The PA cadence for a single oncology patient can exceed 10–20 events over a treatment course. Integrating Otezla's PA into this environment demands robust systems that can manage concurrent authorizations across different benefit types and clinical contexts.

Common Prior Authorization Denial Reasons Impacting Oncology Patients

• Documentation gaps: Missing specific diagnostic criteria or prior therapy details for Otezla's indication, or incomplete oncology-specific documentation for concurrent treatments.
• Step therapy: Payer requires prior failure or contraindication for a less-costly alternative, applicable to many specialty medications including Otezla.
• Off-label use: While less common for Otezla's primary indications, this is a frequent denial reason in oncology for other drugs, highlighting the need for precise medical necessity.
• Medical vs. pharmacy benefit routing errors: Incorrectly routing an oral drug like Otezla through a medical benefit channel, or vice versa for IV oncology drugs.
• NCD/LCD non-coverage: For Medicare Advantage plans, denials based on Original Medicare's coverage rules can impact any prescribed medication.

Klivira's Approach to Integrated Prior Authorization in Oncology

Klivira's platform is engineered to address the distinct challenges of oncology PA, providing a unified solution for high-volume, complex cases. For medications like Otezla, our system streamlines the pharmacy benefit PA process, ensuring it integrates smoothly with the broader medical benefit authorizations for cancer therapies. This comprehensive approach minimizes delays and administrative burden across the patient's entire treatment spectrum.